| Dr John Lawrence Pagano, OD | |
|
9325 Glades Rd Ste 201, Boca Raton, FL 33434-3988 | |
| (561) 488-1001 | |
| Not Available |
| Full Name | Dr John Lawrence Pagano |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 5 Years |
| Location | 9325 Glades Rd Ste 201, Boca Raton, Florida |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1851953566 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | TUV008955-01 (New York) | Secondary |
| 152W00000X | Optometrist | OPC6205 (Florida) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Eye Of Horus Pa | 4981636495 | 3 |
News Archive
Pharmaceutical companies are gearing up for an increase in running late phase cancer vaccine trials following draft guidance issued by the FDA last week.
Brilliant, detailed microscope images help dentists to explain treatment options to patients and involve them in decision-making processes to build trust.
Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.
› Verified 7 days ago
| Provider Name | Eye Of Horus Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1164421418 PECOS PAC ID: 4981636495 Enrollment ID: O20050906000861 |
News Archive
Pharmaceutical companies are gearing up for an increase in running late phase cancer vaccine trials following draft guidance issued by the FDA last week.
Brilliant, detailed microscope images help dentists to explain treatment options to patients and involve them in decision-making processes to build trust.
Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John Lawrence Pagano, OD 2709 154th St, Flushing, NY 11354-1552 Ph: (718) 961-9694 | Dr John Lawrence Pagano, OD 9325 Glades Rd Ste 201, Boca Raton, FL 33434-3988 Ph: (561) 488-1001 |
News Archive
Pharmaceutical companies are gearing up for an increase in running late phase cancer vaccine trials following draft guidance issued by the FDA last week.
Brilliant, detailed microscope images help dentists to explain treatment options to patients and involve them in decision-making processes to build trust.
Cancer was the second leading cause of death in the United States in 2013 and the American Cancer Society expects almost 10,000 new cases in New Mexico this year.
Protox Therapeutics Inc. (TSX: PRX), a leader in the development of receptor targeted fusion proteins, today announced positive 12 month data from its open-label Phase 2 study of PRX302 in males with moderate to severe benign prostatic hyperplasia (BPH). The study results indicate that those patients who received an optimal dose of PRX302 continued to demonstrate significant symptomatic relief at 12 months following a single treatment.
Abaxis, Inc., a medical products company manufacturing point-of-care blood analysis systems, today reported financial results for the third fiscal quarter ended December 31, 2012.
› Verified 7 days ago
Caruso Eye Care Optometrist Medicare: Medicare Enrolled Practice Location: 6000 Glades Rd Ste 1040, Boca Raton, FL 33431 Phone: 561-368-5065 | |
Dr. Tamara Lee Maule, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 8903 Glades Rd, Bay A 1, Boca Raton, FL 33434 Phone: 561-477-3524 Fax: 561-477-3576 | |
At Your Home Eyecare, Pa Optometrist Medicare: Medicare Enrolled Practice Location: 21214 N Sweetwater Ln, Boca Raton, FL 33428 Phone: 954-536-8905 Fax: 954-370-4546 | |
Wayne P Tepper Od Pa Optometrist Medicare: Not Enrolled in Medicare Practice Location: 333 Plaza Real, Boca Raton, FL 33432 Phone: 561-392-8383 | |
Haeun Kim, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6100 Glades Rd Ste 107, Boca Raton, FL 33434 Phone: 561-288-3055 | |
Joann Parise, Optometrist Medicare: Not Enrolled in Medicare Practice Location: 318 E Palmetto Park Rd, Boca Raton, FL 33432 Phone: 561-338-0081 Fax: 561-338-8291 | |
Steven D. Sheiner Od, Pa Optometrist Medicare: Medicare Enrolled Practice Location: 7035 Beracasa Way, Suite 101, Boca Raton, FL 33433 Phone: 561-391-3334 Fax: 561-338-3432 |